Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

Nicolino Ruperto, Hermine I Brunner, Athimalaipet V Ramanan, Gerd Horneff, Rubén Cuttica, Michael Henrickson, Jordi Anton, Alina Lucica Boteanu, Inmaculada Calvo Penades, Kirsten Minden, Heinrike Schmeling, Markus Hufnagel, Jennifer E Weiss, Manuela Pardeo, Kabita Nanda, Johannes Roth, Nadina Rubio-Pérez, Joy C Hsu, Sunethra Wimalasundera, Chris Wells, Kamal Bharucha, Wendy Douglass, Min Bao, Navita L Mallalieu, Alberto Martini, Daniel Lovell, Fabrizio De Benedetti, Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG), Nicolino Ruperto, Hermine I Brunner, Athimalaipet V Ramanan, Gerd Horneff, Rubén Cuttica, Michael Henrickson, Jordi Anton, Alina Lucica Boteanu, Inmaculada Calvo Penades, Kirsten Minden, Heinrike Schmeling, Markus Hufnagel, Jennifer E Weiss, Manuela Pardeo, Kabita Nanda, Johannes Roth, Nadina Rubio-Pérez, Joy C Hsu, Sunethra Wimalasundera, Chris Wells, Kamal Bharucha, Wendy Douglass, Min Bao, Navita L Mallalieu, Alberto Martini, Daniel Lovell, Fabrizio De Benedetti, Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG)

Abstract

Objectives: To determine s.c. tocilizumab (s.c.-TCZ) dosing regimens for systemic JIA (sJIA) and polyarticular JIA (pJIA).

Methods: In two 52-week phase 1 b trials, s.c.-TCZ (162 mg/dose) was administered to sJIA patients every week or every 2 weeks (every 10 days before interim analysis) and to pJIA patients every 2 weeks or every 3 weeks with body weight ≥30 kg or <30 kg, respectively. Primary end points were pharmacokinetics, pharmacodynamics and safety; efficacy was exploratory. Comparisons were made to data from phase 3 trials with i.v. tocilizumab (i.v.-TCZ) in sJIA and pJIA.

Results: Study participants were 51 sJIA patients and 52 pJIA patients aged 1-17 years who received s.c.-TCZ. Steady-state minimum TCZ concentration (Ctrough) >5th percentile of that achieved with i.v.-TCZ was achieved by 49 (96%) sJIA and 52 (100%) pJIA patients. In both populations, pharmacodynamic markers of disease were similar between body weight groups. Improvements in Juvenile Arthritis DAS-71 were comparable between s.c.-TCZ and i.v.-TCZ. By week 52, 53% of sJIA patients and 31% of pJIA patients achieved clinical remission on treatment. Safety was consistent with that of i.v.-TCZ except for injection site reactions, reported by 41.2% and 28.8% of sJIA and pJIA patients, respectively. Infections were reported in 78.4% and 69.2% of patients, respectively. Two sJIA patients died; both deaths were considered to be related to TCZ.

Conclusion: s.c.-TCZ provides exposure and risk/benefit profiles similar to those of i.v.-TCZ. S.c. administration provides an alternative administration route that is more convenient for patients and caregivers and that has potential for in-home use.

Trial registration: ClinicalTrials.gov, https://ichgcp.net/clinical-trials-registry/NCT01904292" title="See in ClinicalTrials.gov">NCT01904292 and NCT01904279.

Keywords: autoinflammatory conditions; biologic therapies; cytokines and inflammatory mediators; inflammation; juvenile idiopathic arthritis.

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Figures

Fig . 1
Fig. 1
Patient disposition in the trial of (A) patients with sJIA and (B) patients with pJIA Withdrawal by patient: TCZ-naive, n = 1. Withdrawal because of lack of efficacy: TCZ-naive, n = 4; TCZ-prior, n = 1. BW: body weight; Q10D: every 10 days; QW: every week; Q2W: every 2 weeks; TCZ: tocilizumab; pJIA: polyarticular JIA; sJIA: systemic JIA.
Fig . 2
Fig. 2
Model-computed median steady-state Cmin and Cmax from s.c. dosing vs i.v. dosing Median values are designated by black lines in the centres of the boxes. Boxes indicate the IQR. Whiskers represent 1.5 × IQR. Horizontal red line denotes the model-computed 5th percentile from the i.v.-TCZ trials. The number of i.v.-TCZ sJIA patients includes all patients randomly assigned to TCZ in part 1 of the i.v.-TCZ trial and any patient who escaped from placebo to TCZ in part 1 for whom a PK sample was available. BW: body weight; Cmax: maximum concentration; Cmin: minimum concentration; IQR: interquartile range; PK: pharmacokinetic; QW: every week; Q2W: every 2 weeks; Q3W: every 3 weeks; TCZ: tocilizumab; sJIA: systemic JIA.
Fig . 3
Fig. 3
sIL-6R concentration-time profiles with s.c.-TCZ treatment of TCZ-prior (A, B) and TCZ-naive (C, D) patients Data are shown as median (IQR) values. Error bars = IQR. BW: body weight; IQR: interquartile range; Q10D: every 10 days; QW: every week; Q2W: every 2 weeks; Q3W: every 3 weeks; sIL-6R: serum IL-6 receptor; TCZ: tocilizumab.
Fig . 4
Fig. 4
JADAS-71 over time for sJIA and pJIA patients treated with s.c.-TCZ Data are shown as median (IQR) valuesData points at weeks 4 and 8 for the 10.5). BW: body weight; IQR: interquartile range; JADAS-71: Juvenile Arthritis DAS including 71 joints; pJIA: polyarticular JIA; Q10D: every 10 days; QW: every week; Q2W: every 2 weeks; Q3W: every 3 weeks; s.c.-TCZ: subcutaneous tocilizumab; sJIA: systemic JIA; TCZ: tocilizumab.

References

    1. Ravelli A, Martini A.. Juvenile idiopathic arthritis. Lancet 2007;369:767–78.
    1. Prakken B, Albani S, Martini A.. Juvenile idiopathic arthritis. Lancet 2011;377:2138–49.
    1. Martini A, Ravelli A, Avcin T, for the Paediatric Rheumatology International Trials Organization (PRINTO) et al.Toward new classification criteria for juvenile idiopathic arthritis: first steps, Paediatric Rheumatology International Trials Organization International Consensus. J Rheumatol 2019;46:190–7.
    1. Guzman J, Oen K, Tucker LB. et al.The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis 2015;74:1854–60.
    1. Oen K, Guzman J, Dufault B, the Research in Arthritis in Canadian Children emphasizing Outcomes (ReACCh-Out) investigators et al.Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis. Arthritis Care Res 2018;70:134–44.
    1. Grevich S, Shenoi S.. Update on the management of systemic juvenile idiopathic arthritis and role of IL-1 and IL-6 inhibition. Adolesc Health Med Ther 2017;8:125–35.
    1. Canny S, Mellins E.. New frontiers in the treatment of systemic juvenile idiopathic arthritis. F1000Res 2017;6:971.
    1. De Benedetti F, Massa M, Robbioni P. et al.Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158–63.
    1. De Benedetti F, Robbioni P, Massa M. et al.Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol 1992;10:493–8.
    1. Mangge H, Kenzian H, Gallistl S. et al.Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211–20.
    1. De Benedetti F, Pignatti P, Gerloni V. et al.Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997;24:1403–9.
    1. Mihara M, Kasutani K, Okazaki M. et al.Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731–40.
    1. Rose-John -6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8:1237–47.
    1. De Benedetti F, Brunner HI, Ruperto N. et al.Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95.
    1. Brunner HI, Ruperto N, Zuber Z, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG) et al.Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015;74:1110–7.
    1. Smolen JS, Beaulieu A, Rubbert-Roth A. et al.Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–97.
    1. Genovese MC, McKay JD, Nasonov EL. et al.Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968–80.
    1. Burmester GR, Rubbert-Roth A, Cantagrel A. et al.Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA). Ann Rheum Dis 2016;75:68–74.
    1. Besada E.Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence 2014;8:1051–9.
    1. Barton JL.Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009;3:335–44.
    1. Chilton F, Collett RA.. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008;6:1–14.
    1. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
    1. Wang Y, Jadhav PR, Lala M, Gobburu JV.. Clarification on precision criteria to derive sample size when designing paediatric pharmacokinetic studies. J Clin Pharmacol 2012;52:1601–6.
    1. Petty RE, Southwood TR, Manners P, International League of Associations for Rheumatology et al.International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.
    1. Ruperto N, Martini A.. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596–601.
    1. Brunner HI, Rider LG, Kingsbury DJ, for the PRCSG Advisory Council et al.Paediatric Rheumatology Collaborative Study Group—over four decades of pivotal clinical drug research in paediatric rheumatology. Pediatr Rheumatol Online J 2018;16:45.
    1. Stubenrauch K, Wessels U, Birnboeck H. et al.Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010;32:1597–609.
    1. Consolaro A, Ruperto N, Bazso A, Paediatric Rheumatology International Trials Organisation et al.Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66.
    1. Consolaro A, Bracciolini G, Ruperto N, for the Paediatric Rheumatology International Trials Organization et al.Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012;64:2366–74.
    1. Consolaro A, Ruperto N, Bracciolini G, for the Paediatric Rheumatology International Trials Organization (PRINTO) et al.Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis 2014;73:1380–3.
    1. Consolaro A, Negro G, Chiara Gallo M. et al.Defining criteria for disease activity states in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. Arthritis Care Res 2014;66:1703–9.
    1. Wallace CA, Giannini EH, Huang B, Itert L, Ruperto N, Childhood Arthritis Rheumatology Research Alliance (CARRA) American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res 2011;63:929–36.
    1. Ruperto N, Ravelli A, Pistorio A. et al.Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001;19:S1–9.
    1. De Benedetti F, Brunner H, Ruperto N, for the Paediatric Rheumatology International Trials Organisation and the Paediatric Rheumatology Collaborative Study Group et al.Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol 2015;67:840–8.
    1. Bharucha KN, Brunner HI, Calvo Penades I, for the Paediatric Rheumatology International Trials Organisation and the Paediatric Rheumatology Collaborative Study Group et al.Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial. J Rheumatol 2018;45:1173–9.
    1. US Food and Drug Administration. Guidance for Industry: Exposure–Response Relationships—Study Design, Data Analysis, and Regulatory Applications. Rockville, MD, April 2003. . (30 June 2020, date last accessed).
    1. European Medicines Agency. ICH Topic E 5 (R1): Ethnic Factors in the Acceptability of Foreign Clinical Data. London, 1998. . (30 June 2020, date last accessed).
    1. Genentech, Inc. ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use. South San Francisco, CA: Genentech, Inc, December 2018.
    1. Roche Products Ltd. RoActemra 20mg/ml concentrate for solution for infusion. Hertfordshire, UK: Roche Products Ltd, November 2018.
    1. Zhang X, Chen YC, Terao K.. Clinical pharmacology of tocilizumab for the treatment of polyarticular-course juvenile idiopathic arthritis. Expert Rev Clin Pharmacol 2017;10:471–82.
    1. Nishimoto N, Terao K, Mima T. et al.Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959–64.
    1. Kivitz A, Wallace T, Olech E. et al.Long-term safety and efficacy of subcutaneously administered tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term extension study. Rheumatol Ther 2016;3:291–304.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit